HomeBUSINESS
BUSINESS

MSD, Astellas to Copromote Januvia-Suglat Combo
(Nov.29.2017)

MSD and Astellas Pharma said on November 28 that they have sealed a definite accord for the copromotion of a fixed-dose combination paring Januvia (sitagliptin) and Suglat (ipragliflozin) - which are the first-in-class DPP-4 inhibitor and SGLT-2 inhibitor in Japan sold by the respective companies ...
(LOG IN FOR FULL STORY)

News Calendar